Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pershing Square, Valeant to appear in court on insider trading suit settlement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 07:16am CEST
Ackman, CEO of Pershing Square Capital, speaks at the WSJ Digital Conference in Laguna Beach

(Reuters) - A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and activist investor Bill Ackman's Pershing Square (>> Pershing Square Holdings) to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit.

(Reuters) - A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and activist investor Bill Ackman's Pershing Square (>> Pershing Square Holdings) to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit.

The hearing, set for Jan. 16, comes after Pershing Square and Valeant last week decided to pay $290 million to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc (>> Allergan plc) in 2014.

The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan.

The court has "substantial questions regarding whether the settlement amount is reasonable and fair," according to documents filed in the U.S. District Court, Central District of California.

"Today's order is a mandated step in the settlement process," a Valeant spokeswoman said in an email to Reuters. "We believe the settlement is fair, reasonable and adequate, and we look forward to explaining our position to the Court."

Pershing Square could not be reached for comment outside regular business hours.

(Reporting by Abinaya Vijayaraghavan in Bengaluru; Editing by Amrutha Gayathri)

Stocks mentioned in the article
ChangeLast1st jan.
PERSHING SQUARE HOLDINGS -1.25% 12.6 Delayed Quote.-6.66%
VALEANT PHARMACEUTICALS INTL INC 1.03% 22.63 Delayed Quote.-14.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
06:25pShire willing to back $64 billion Takeda bid, market signals doubts
RE
02:16pShire willing to back $64 billion Takeda bid, market signals doubts
RE
04/24Shire receives new bid from Takeda as takeover deadline looms
RE
04/24BIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
PU
04/20Shire rejects third Takeda bid, Allergan mulling offer
AQ
04/20Shire rejects third Takeda bid, as Allergan drops out
AQ
04/20Shire Attracts Flurry Of Suitors -- WSJ
DJ
More news
News from SeekingAlpha
12:01pOrphoMed's lead candidate Fast Track'd for IBS-D 
04/24Conatus Pharmaceuticals; Upcoming Phase 2b Liver Results And Other Pipeline P.. 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/24Premarket analyst action - healthcare 
04/24If Takeda Walks Then Shire Could Crater 
Financials ($)
Sales 2018 15 225 M
EBIT 2018 7 285 M
Net income 2018 -908 M
Debt 2018 23 926 M
Yield 2018 1,85%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,20x
EV / Sales 2019 4,86x
Capitalization 55 279 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 208 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.26%55 279
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398